Share on StockTwits

Applied Genetic Technologies Corp (NASDAQ:AGTC)‘s stock had its “buy” rating reiterated by research analysts at Cantor Fitzgerald in a report released on Thursday. They currently have a $24.00 target price on the stock, up from their previous target price of $21.00. Cantor Fitzgerald’s price target would suggest a potential upside of 31.80% from the company’s current price.

Applied Genetic Technologies Corp (NASDAQ:AGTC) traded down 1.37% on Thursday, hitting $17.96. The stock had a trading volume of 3,269 shares. Applied Genetic Technologies Corp has a one year low of $11.10 and a one year high of $34.37. The stock has a 50-day moving average of $18.59 and a 200-day moving average of $17.91. The company’s market cap is $288.8 million.

Separately, analysts at BMO Capital Markets raised their price target on shares of Applied Genetic Technologies Corp from $21.00 to $34.00 in a research note on Monday, June 9th. They now have an “outperform” rating on the stock.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.